Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

4.76
-0.2400-4.80%
Pre-market: 4.71-0.0481-1.01%07:32 EDT
Volume:58.20K
Turnover:279.44K
Market Cap:47.81M
PE:-1.97
High:5.00
Open:4.93
Low:4.71
Close:5.00
52wk High:29.98
52wk Low:4.32
Shares:10.04M
Float Shares:8.83M
Volume Ratio:0.76
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4137
EPS(LYR):0.6400
ROE:-66.57%
ROA:-39.85%
PB:1.38
PE(LYR):7.44

Loading ...

Seres Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
Aug 14

Seres Therapeutics - May Offer up to $300 Mln of Securities - SEC Filing

THOMSON REUTERS
·
Aug 14

Seres Therapeutics (MCRB) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Aug 05

Seres Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate

Benzinga Earnings
·
Aug 05

Seres Therapeutics Q2 Net Income Turns Positive on VOWST Sale Gain

Reuters
·
Aug 05

Seres Therapeutics Returns to Q2 FY26 Net Income of 4.58 Million; Revenue Rises to 736,000

Reuters
·
Aug 05

Seres Therapeutics Q2 EPS USD 0.47

Reuters
·
Aug 05

Seres Therapeutics Q2 Collaboration Revenue USD 736 Thousand

THOMSON REUTERS
·
Aug 05

Seres Therapeutics Q2 Operating Expenses USD 22.009 Million

THOMSON REUTERS
·
Aug 05

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

THOMSON REUTERS
·
Aug 05

Seres Therapeutics - on July 31, Entered Agreement to Terminate Lease Early with Bmr-Sidney Research Campus Llc , Reducing Facilities Costs

THOMSON REUTERS
·
Aug 05

Achieve Life Sciences Names Ronald Dadino SVP of CMC and Supply Chain

Reuters
·
Aug 03

Seres Therapeutics Inc Expected to Post a Loss of $2.18 a Share - Earnings Preview

Reuters
·
Jul 31

Seres Therapeutics Shareholders Approve Directors and Executive Pay

TIPRANKS
·
Jul 09

Seres Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Seres Therapeutics (MCRB)

TIPRANKS
·
Jul 09

Seres Therapeutics Explores Partnerships to Advance Ser-155 Development in Immune Checkpoint Inhibitor-related Enterocolitis

Reuters
·
Jul 08

Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell

MT Newswires Live
·
Jul 08

Seres Therapeutics announces top-line results from SER-155 trial

TIPRANKS
·
Jul 08